These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11369431)

  • 1. HIV fusion and its inhibition.
    LaBranche CC; Galasso G; Moore JP; Bolognesi DP; Hirsch MS; Hammer SM
    Antiviral Res; 2001 May; 50(2):95-115. PubMed ID: 11369431
    [No Abstract]   [Full Text] [Related]  

  • 2. The potential for HIV fusion inhibition.
    Cammack N
    Curr Opin Infect Dis; 2001 Feb; 14(1):13-6. PubMed ID: 11979109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion inhibitors: T-20 and T-1249.
    TreatmentUpdate; 2001; 12(12):2-3. PubMed ID: 11570088
    [No Abstract]   [Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.
    Ketas TJ; Frank I; Klasse PJ; Sullivan BM; Gardner JP; Spenlehauer C; Nesin M; Olson WC; Moore JP; Pope M
    J Virol; 2003 Feb; 77(4):2762-7. PubMed ID: 12552019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to HIV-1 entry inhibitors.
    Olson WC; Maddon PJ
    Curr Drug Targets Infect Disord; 2003 Dec; 3(4):283-94. PubMed ID: 14754430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Katy, bar the door! HIV entry inhibitors.
    Martinez LJ
    Res Initiat Treat Action; 2000 Jun; 6(2):6-12. PubMed ID: 11707878
    [No Abstract]   [Full Text] [Related]  

  • 7. 9th National Retrovirus Conference: new treatments, new choices.
    Laurence J
    AIDS Patient Care STDS; 2002 May; 16(5):193-5. PubMed ID: 12055025
    [No Abstract]   [Full Text] [Related]  

  • 8. Preventing viral entry. Fusion inhibitors.
    Marks N
    Posit Living; 1999 Mar; 8(2):13. PubMed ID: 12491997
    [No Abstract]   [Full Text] [Related]  

  • 9. Capture of an early fusion-active conformation of HIV-1 gp41.
    Furuta RA; Wild CT; Weng Y; Weiss CD
    Nat Struct Biol; 1998 Apr; 5(4):276-9. PubMed ID: 9546217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Picture story. Keeping HIV out.
    Konforti B
    Nat Struct Biol; 1999 Nov; 6(11):1004. PubMed ID: 10542088
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid.
    van Lelyveld SF; Nijhuis M; Baatz F; Wilting I; van den Bergh WM; Kurowski M; de Jong D; Hoepelman AI; Wensing AM
    Clin Infect Dis; 2010 Feb; 50(3):387-90. PubMed ID: 20047481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entry inhibitor combination shows promise.
    AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11228623
    [No Abstract]   [Full Text] [Related]  

  • 13. [T-20: a fusion inhibitor].
    Iafolla M
    Sidahora; 2002; (3):20-2. PubMed ID: 12703471
    [No Abstract]   [Full Text] [Related]  

  • 14. What's taking T-20 so long?
    Huff B
    GMHC Treat Issues; 2001 Apr; 15(4):1-3. PubMed ID: 11590938
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV genetic mutations causing resistance to the new drug T-20: recent findings.
    Bean P
    Am Clin Lab; 2002 Oct; 21(8):15-6. PubMed ID: 12440170
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of virus entry: an antiviral mechanism of emerging prominence.
    Koszalka GW; Meanwell NA
    Curr Opin Investig Drugs; 2006 Feb; 7(2):106-8. PubMed ID: 16499279
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.
    Melby T; Despirito M; Demasi R; Heilek-Snyder G; Greenberg ML; Graham N
    J Infect Dis; 2006 Jul; 194(2):238-46. PubMed ID: 16779731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100.
    Tremblay CL; Kollmann C; Giguel F; Chou TC; Hirsch MS
    J Acquir Immune Defic Syndr; 2000 Oct; 25(2):99-102. PubMed ID: 11103038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.